Introduction
Tyrosine kinase fusions, including BCR-ABL and TEL-PDGFβR, are well-validated therapeutic targets in human leukemias (1) . Small molecule inhibitors, such as imatinib, are effective therapies for BCR-ABL-and TEL-PDGFβR-mediated leukemias. Imatinib is a selective inhibitor of tyrosine kinases, including ABL, PDGFβR, PDGFRα, ABL-related gene (ARG), and human cellular homolog of v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene (c-KIT) (2) . Imatinib has been demonstrated to be safe and effective in the clinical treatment of BCR-ABL-positive chronic myelogenous leukemia (CML) and TEL-PDGFβR-induced chronic myelomonocytic leukemia (CMML), as well as in the treatment of other solid tumors such as gastrointestinal stromal cell tumors (GIST) associated with activating mutations of c-KIT (3) (4) (5) . However, imatinib is not curative as a single agent, and clinical resistance may develop. Drug-resistance point mutations in the ABL kinase domain of BCR-ABL and overexpression of BCR-ABL have been identified in patients who relapsed while on imatinib therapy (2, (6) (7) (8) (9) . Therefore, the development of alternative molecularly targeted therapies that might enhance specificity and clinical efficacy, as well as overcome the problem of resistance, is of great clinical interest.
Chromosomal translocations are recurrent findings in leukemias and some solid tumors, and they frequently result in abnormal expression of chimeric fusion oncoproteins (1) . The unique fusion junctions of these molecules are attractive candidates for molecularly targeted therapeutic intervention using RNA interference (RNAi). RNAi is an evolutionarily conserved process of posttranscriptional suppression of gene expression and is mediated by 21-to 23-nucleotide (nt) sequence-specific doublestranded small interfering RNA (siRNA) in mammalian cells without initiating the nonspecific double-stranded RNA responses (10) (11) (12) . Chemically synthesized siRNAs targeting the BCR-ABL fusion junction have been tested for reduction in BCR-ABL protein expression in leukemia cells (13) (14) (15) . However, the limitation of such an oligonucleotide-based system is that the delivery of siRNA to mammalian cells largely depends on transfection efficiency, and for many hematopoietic cell lines as well as primary cell lines, efficient transfection cannot be achieved. Moreover, transfected siRNA cannot induce RNAi over a long-term period. One solution is to express the specific siRNA molecules in cells. The intracellular transcription of siRNAs has been achieved by using pol III-dependent promoters, such as the small nuclear RNA (snRNA) U6 promoter and the human RNAse P RNA H1 promoter, to drive expression of short hairpin RNAs that are processed into siRNAs in mammalian cells (16) (17) (18) (19) .
The TEL-PDGFβR fusion was identified as a consequence of t(5;12)(q33;p13) chromosomal translocation, a recurring cytogenetic abnormality associated with CMML that is characterized by abnormal myelopoiesis with eosinophilia, myelofibrosis, and fre-quent progression to acute myeloid leukemia (20) . Imatinib inhibits the growth of cells expressing TEL-PDGFR fusion protein and has been demonstrated to be effective in the clinical treatment of CMML induced by TEL-PDGFβR (5, 21) . As presented in this report, we have developed a retroviral system for stable expression of siRNA directed to the unique junction sequences of fusion tyrosine kinases in transformed hematopoietic cells. We investigated the utility of siRNAs alone or in combination with small molecule inhibitors to impair TEL-PDGFβR-mediated hematopoietic transformation. Moreover, an inhibitory siRNA-based strategy was useful to overcome the resistance of a TEL-PDGFβR mutant to imatinib.
Methods

Vectors.
The human pol III promoter H1 was cloned from genomic DNA by PCR and inserted into pBluescript II as described to make pSUPER (22) . The oligonucleotides encoding the TEL-PDGFβR siRNA (TPsiRNA) were 5ʹ-GATCCCCTGAAGAAGC CTT-GCCCTTTTTCAAGAGAAAAGGGCAAGGCTTCTTCATTTTT-GGAAA-3ʹ and 5ʹ-AGCTTTTCCAAAAATGAAGAAGCCTT-GCCCTTTTCTCTTGAAAAAGGGCAAGGCTTCTTCAGGG-3ʹ. These oligonucleotides were annealed and subcloned to downstream of the H1 promoter in pSUPER by using HindIII and BglII. The resulting H1_TPsiRNA cassette was subcloned into 3ʹ Δ long tandem repeat (ΔLTR) of pQCXIP vector (BD Biosciences Clontech, Palo Alto, California, USA) by using NheI to generate pQCXIP_ H1_TPsiRNA. The H1 promoter was also subcloned into 3ʹ LTR pQCXIP by using NheI with the introduction of XhoI and HpaI sites following H1. The oligonucleotides encoding the NPM-ALK siRNA were 5ʹ-TCGACCCATGAAGAAGCCTTGCCCTTTTCAAGAGA-AAGGGCAAGGCTTCTTCATTTTTTGGAAAGTT-3ʹ and 5ʹ-AACTTTCCAAAAAATGAAGAAGCCTTGCCCTTTCTCTT-GAAAAGGGCAAGGCTTCTTCATGGG-3ʹ. These oligonucleotides were annealed and subcloned to downstream of the H1 promoter in pQCXIP by using XhoI and HpaI to generate pQCXIP_H1_NAsiR-NA. Mutation T681I was introduced into TEL-PDGFβR by using the QuikChange-XL site-directed mutagenesis kit according to the manufacturer's instructions (Stratagene, La Jolla, California, USA) using pMSCV-neoEB-TEL-PDGFβR as a template. The primer used was 5ʹ-GGAGGACCCATCTATATCATCATTGAGTACTGCC-GCTACGGAGAC-3ʹ.
Ba/F3 cell culture and retroviral transduction. Ba/F3 cells were cultured in RPMI 1640 medium with 10% FBS and 1.0 ng/ml IL-3. The 293T cells used to generate the siRNA retroviral supernatant were cultured in DMEM with 10% FBS. To generate Ba/F3 cell lines stably expressing siRNA, 1 × 10 6 TEL-PDGFβR or nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) neomycin-resistant stable Ba/F3 cells were transduced with retroviral supernatant carrying pQCXIP_H1_TPsiRNA or pQCXIP_H1_NAsiRNA, respectively, in the presence of Polybrene (10 μg/ml) and cultured for 48 hours. The cells were then selected with 1.0 mg/ml G418 and 1.0 ng/ml puromycin in the presence of IL-3 for another 8-10 days. To assess IL-3-independent outgrowth, Ba/F3 cells were washed three times with RPMI and cultured in RPMI with 10% FBS without IL-3. The number of live cells was determined by trypan blue staining and was scored daily. For cell viability assay, 1 × 10 5 Ba/F3 cells were cultured in 24-well plates under the condition of IL-3 withdrawal and, in some instances, chemotherapeutic drugs. The number of viable cells at each experimental time point was determined by using the Celltiter96AQ uesous one solution proliferation kit (Promega Corp., Madison, Wisconsin, USA).
Mice. Athymic nude mice were each injected with 1 × 10 6 Ba/F3 cells stably expressing TEL-PDGFβR with or without TPsiRNA, or Ba/F3 cells transduced with empty vector as control, via marginal tail vein (n = 4 for each Ba/F3 cell line). In a second study, syngeneic Balb/C mice were injected with variant Ba/F3 cells (n = 4 for empty vector and TEL-PDGFβR control cell lines; n = 8 for cells stably expressing TEL-PDGFβR and TPsiRNA). The log rank test was used to assess statistical significance for differences in survival.
Western blotting analysis. To assay for the phosphorylation level of various different proteins, Ba/F3 cells were treated with serum starvation and in some instances imatinib at increasing concentrations for 4 hours prior to lysis. The cell extracts were applied to immunoprecipitation with various antibodies and the protein G-Sepharose (Amersham Pharmacia, Piscataway, New Jersey, USA). Immunocomplexes were resolved on SDS/PAGE (12.5%) for Western blotting. Antibodies used included anti-PDGFβR tail serum (BD Biosciences Pharmingen, San Diego, California, USA); anti-PI3K (p85) antiserum, 4G10 anti-phosphotyrosine antibody (Upstate Biotechnology, Lake Placid, New York, USA); antibodies recognizing STAT5b and phospho-PI3K p85 (Tyr-508) (Santa Cruz Biotechnology, Santa Cruz, California, USA); phospho-STAT5 (Tyr-694), STAT3, phospho-STAT3 (Tyr-705), phospholipase C (PLCγ) and phosphor-PLCγ (Tyr-783) (Cell Signaling Technology, Beverly, Massachusetts, USA).
RT-PCR and Northern blotting. Whole RNA was isolated from Ba/ F3 cells using the RNeasy Mini Kit (QIAGEN, Valencia, California, USA). Primers designed to specifically amplify the TEL-PDGFβR breakpoint region are 5ʹ-CAGCCGGAGGTCATACTGG-3ʹ and 5ʹ-GCATGATGAGGATGATAAGGG-3ʹ. The RT-PCR reactions were performed using QuantiTect SYBR Green RT-PCR kit (QIAGEN) on an iCycler iQ Multi-Color Real Time PCR Detection system (Bio-Rad Laboratories, Hercules, California, USA). TEL-PDGFβR mRNA level was normalized against endogenous GAPDH mRNA level. For Northern blotting, total RNA was isolated using TRIZOL Reagent (Invitrogen Life Technologies, Carlsbad, California, USA) from Ba/F3 cells. RNA (30 μg) was applied onto 12% (wt/vol) polyacrylamide-urea gels and transferred by electroblotting onto ZetaProbe GT nylon membranes (Bio-Rad Laboratories). Membranes were prehybridized and hybridized using ExpressHyb Hybridization Solution (BD Biosciences Clontech) following manufacturer's instructions. TPsiRNA was probed by 32 P-labeled antisense oligonucleotides (5ʹ-TGAAGAAGCCTTGCCCTTT-3ʹ) for 1 hour at 42°C and visualized by autoradiography.
Results
Retroviral delivery of siRNA directed against TEL-PDGFβR breakpoint into hematopoietic cells.
To target the unique fusion junction sequence in TEL-PDGFβR, a 19-bp stem-loop structure was designed as described previously for siRNA expression (22) , including a 19-nt sense strand of target sequence that is derived from the breakpoint of the TEL-PDGFβR gene and a short spacer sequence that is followed by a reverse complement of the same 19-nt sequence ( Figure 1A) . We cloned the human pol III-dependent RNAse P RNA H1 promoter from genomic DNA and subcloned the H1 promoter followed by the siRNA hairpin cassette into the 3ʹ LTR of pQCXIP, a self-inactivating (SIN) retroviral vector to minimize potential promoter interference from the viral 5ʹ LTR ( Figure 1B ). This strategy results in two copies of the H1-siRNA cassette after reverse transcription of the integrated provirus in the 5ʹ and 3ʹ LTR, respectively, which has been reported to generate higher levels of siRNA and enhanced inhibition of target genes (23).
We first tested the effect of the expressed siRNA on TEL-PDGFβR expression in Ba/F3 cells stably transduced with TEL-PDGFβR. The retroviral vector (pQCXIP_H1_TPsiRNA) containing the cassette of H1-driven TPsiRNA and a puromycin resistance gene was introduced into Ba/F3 cells stably expressing TEL-PDGFβR. Western blot analysis of cells selected for resistance to puromycin demonstrated suppression of TEL-PDGFβR protein expression ( Figure 1C ). Real-time RT-PCR analysis showed an approximately 4,000-fold decrease in mRNA level of TEL-PDGFβR ( Figure 1D ), but no decrease was detected in the mRNA level of native TEL or PDGFβR by RT-PCR (data not shown) in the cells following retroviral transduction of pQCXIP_H1_TPsiRNA. These results demonstrate that TEL-PDGFβR-derived siRNA is highly specific for suppression of the fusion tyrosine kinase. Furthermore, Northern blot analysis confirmed expression of the 21-nt siRNA in RNA samples derived from cells transduced with pQCXIP_H1_TPsiRNA using an oligonucleotide directed to the antisense 19-nt target sequence as a probe ( Figure 1E ). Taken together, these data demonstrate stable expression of siRNA directed against the TEL-PDGFβR fusion junction sequence in hematopoietic cells, and persistent reduction in TEL-PDGFβR mRNA and protein expression was observed.
Stable siRNA expression inhibits TEL-PDGFβR in vitro and in vivo. Although TEL-PDGFβR protein was markedly reduced by the siRNA, there was a residual low level of target protein expression ( Figure 1, C and D) . Therefore, we next assessed the functional effects of inhibition of TEL-PDGFβR expression in Ba/F3 cells. Ba/F3 cells stably expressing TEL-PDGFβR with or without coexpression of inhibitory TPsiRNA were assayed for ability to confer IL-3-independent growth. As reported previously (24), TEL-PDGFβR transformed Ba/F3 cells to IL-3 factor-independent growth, and the control Ba/F3 cells transduced with empty vector alone underwent apoptotic cell death in the absence of IL-3. In contrast, TEL-PDGFβR-transformed Ba/F3 cells that were stably transduced with TPsiRNA had a significantly slower proliferative rate than cells expressing wild-type TEL-PDGFβR alone (Figure 2A) , as well as reduced TEL-PDGFβR expression and tyrosine autophosphorylation ( Figure 2B ). Thus, knockdown of TEL-PDGFβR with siRNA impaired the growth of transformed cells but did not cause full reversion to IL-3 dependence. These findings correlated with a marked decrement, but not abrogation, in activation of downstream effectors of TEL-PDGFβR including STAT5, PI3K, STAT3 or PLCγ, respectively (Figure 2, C-F) .
To evaluate the potential therapeutic efficacy of TPsiRNA in vivo, we used a murine mouse model in which 1 × 10 6 TEL-PDGFβR-transformed Ba/F3 cells or TEL-PDGFβR-transformed Ba/F3 cells coexpressing the TPsiRNA were injected into the tail vein of nude mice ( Figure 2G results were obtained in a second study in which Ba/F3 cells were injected into syngeneic Balb/C mice. When compared with the control group injected with TEL-PDGFβR stable cells, a significant increase in survival was observed in animals injected with TEL-PDGFβR cells expressing siRNA (P = 0.00002; Figure 2H ). These data indicate that TPsiRNA expression markedly attenuates the efficacy of TEL-PDGFβR-mediated tumorigenesis in this murine allograft model. However, TPsiRNA expression alone in this context is not sufficient to abrogate TEL-PDGFβR-induced transformation.
Stable siRNA expression sensitizes TEL-PDGFβR for small molecule inhibitors and overcomes drug resistance. We next tested for possible synergistic effects between inhibitory siRNA and imatinib, a small molecule inhibitor of TEL-PDGFβR tyrosine kinase activity. Imatinib inhibits the growth of TEL-PDGFR-transformed cells and is effective in the clinical treatment of CMML induced by TEL-PDGFβR (5, 21) . Doseresponse curves demonstrated that TEL-PDGFβR-transformed Ba/ F3 cells expressing the TPsiRNA were sensitized to imatinib in a cell viability assay ( Figure 3A) . For example, the IC 50 of TEL-PDGFβR-transformed cells for imatinib was approximately 50 nM, whereas the IC 50 for cells coexpressing the TPsiRNA was approximately 10 nM. Moreover, the Western blot results showed that stable expression of TPsiRNA sensitized TEL-PDGFβR to inhibition by imatinib in autophosphorylation activity of TEL-PDGFβR, as well as activation of TEL-PDGFβR downstream effectors including STAT5, PI3K or PLCγ (Figure 3B ). At high concentrations of imatinib (>100 nM), coexpression of TPsiRNA almost completely abrogated the kinase activity of TEL-PDGFβR ( Figure 3B ), which correlated with the nearly full reversion to IL-3 dependence of the growth of transformed cells with the same treatments ( Figure 3A) . These data provide the signaling basis for a mechanism by which suppression of TEL-PDGFβR expression by siRNA sensitizes transformed cells to imatinib.
We also tested the effect of the mammalian target of rapamycin (mTOR) inhibitor rapamycin (25) on TEL-PDGFβR-transformed cells in the presence or absence of TPsiRNA. mTOR is a serine/threonine kinase, and the IGFR-PI3K-Akt-mTOR signaling pathway is crucial for cell growth and survival (26) . As a surrogate for mTOR activation, we evaluated one of the mTOR substrates, p70 S6 kinase (27) , which is phosphorylated and activated in TEL-PDGFβR-transformed cells ( Figure 3D ). Rapamycin alone was a potent inhibitor of cell growth in TEL-PDGFβR-transformed Ba/F3 cells ( Figure 3C ). Furthermore, rapamycin in combination with TPsiRNA expression was more effective than either agent alone in the inhibition of TEL-PDGFβR-transformed Ba/F3 cells ( Figure 3C ). Similar results were obtained in silencing fusion tyrosine kinase NPM-ALK, which is associated with human anaplastic large-cell lymphoma (ALCL) (28) , by the stable expression of fusion junction-specific siRNA and the addition of rapamycin (Figure 3, E-G) , indicating that the strategy can be extrapolated to other oncogenic fusion tyrosine kinases.
Collectively, these data indicate that expression of siRNA targeting fusion tyrosine kinases can enhance the efficacy of cell killing in combination with inhibitors of the tyrosine kinases themselves or their downstream effectors.
We also investigated the potential use of inhibitory siRNA as a strategy to inhibit imatinib-resistant mutants of TEL-PDGFβR. A potential imatinib-resistant mutation T681I was introduced into TEL-PDGFβR. The T681I mutation in the context of PDGFβR corresponds to the T315I mutation in ABL, a common resistance mutation in BCR-ABL + CML patients who relapse while on imatinib therapy (6, 7) . Similarly, TEL-PDGFβR T681I mutant showed resistance to imatinib. The IL-3-independent proliferation of Ba/F3 cells transduced with TEL-PDGFβR T681I was not inhibited at concentrations of imatinib as high as 1.0 μM ( Figure 4A ). Consistent with our previous results, stable expression of TPsiRNA not only decreased TEL-PDGFβR T681I protein expression (Figure 4B) , but resulted in a significantly slower proliferative rate of TEL-PDGFβR T681I-transduced Ba/F3 cells compared with cells expressing either TEL-PDGFβR wild type or T681I mutant alone (Figure 4, C and D) . The majority of cells coexpressing TEL-PDGFβR T681I and TPsiRNA underwent apoptosis and died by day 4 in the absence of IL-3 ( Figure 4D ). In addition, we found that the imatinib-resistant TEL-PDGFβR T681I mutant was efficiently inhibited by an alternative small molecule inhibitor PKC412 ( Figure 4E ). PKC412 is an inhibitor of FMS-like receptor tyrosine kinase 3 (FLT3), PKC, kinase insert domain receptor (KDR) c-KIT, PDGFRα and PDGFβR (29) (30) (31) , and this agent is currently being evaluated as molecularly-targeted therapy in a phase II clinical trial for AML patients with FLT3 activating mutations (32) . Moreover, the dose-response curves demonstrated that, although TEL-PDGFβR T681I-transformed Ba/F3 cells were not sensitized to imatinib by coexpression of TPsiRNA (data not shown), they were sensitized to PKC412 ( Figure 4E ). The IC 50 of TEL-PDGFβR T681I-transformed cells for PKC412 is approximately 400 nM, which is decreased to approximately 100 nM by coexpression of TPsiRNA ( Figure 4E ). Taken together, these data demonstrate that the expression of siRNA not only enhances the efficacy of inhibition by small molecule inhibitors of susceptible tyrosine kinases but may also be useful for the inhibition of mutant tyrosine kinases that are resistant to small molecule inhibitors.
Discussion
In this study, we present a retroviral delivery system for stable expression of siRNA directed against the unique fusion junction sequence of TEL-PDGFβR in transformed hematopoietic cells. This retrovirus-based method allows for stable expression of siRNA in mammalian cells and overcomes the problems of poor transfection efficiency of small RNAs into many hematopoietic cell lines. Moreover, because the provirus containing siRNA expression cassette is integrated into the genome of the stably transduced cells, this system also provides a useful tool for monitoring the long-term effects of stably expressing siRNA in hematopoietic cells.
Stable expression of the siRNA markedly inhibits TEL-PDGFβR expression and activation of its downstream signaling effectors. In addition, our results showing inhibition of NPM-ALK by using siRNA directed to the fusion junction indicate that this approach may be broadly applicable for the inhibition of oncogenic fusion proteins. Although the TEL-PDGFβR protein level is markedly reduced by expression of TEL-PDGFβR-specific siRNA (TPsiR-NA), there is a residual low level of target protein expression. Our results indicate that expression of siRNA alone is effective, but not sufficient, to completely abrogate TEL-PDGFβR-induced transformation in cell culture and murine allograft models. However, our data demonstrate that stable expression of siRNA sensitizes TEL-PDGFβR-transformed cells to the small molecule inhibitors imatinib and rapamycin. These findings indicate that siRNA directed to the unique fusion junction sequences of the target fusion tyrosine kinases can enhance the efficacy of cell killing by other molecularly targeted therapies, such as direct inhibitors of the tyrosine kinases themselves or indirect inhibitors of their downstream signaling pathways. It is possible to enhance the siRNA inhibitory effect by designing vectors that contain multiple copies of siRNA expression cassettes or by superinfection strategies.
Moreover, expression of TPsiRNA effectively inhibits an imatinib-resistant mutant of TEL-PDGFβR, indicating that this siRNA approach provides a strategy opportunity to overcome clinically identified drug resistance. In addition, the imatinibresistant TEL-PDGFβR T681I mutant is efficiently inhibited by PKC412. In contrast to imatinib, which binds to and inhibits ABL by trapping the kinase in an inactive conformation (33, 34) , PKC412 is a derivative of staurosporine and may inhibit the target kinases by binding within the ATP-binding pocket of the active conformation (35, 36) , thus inhibiting the TEL-PDGFβR imatinib-resistant mutant. Indeed, we reported previously that PKC412 effectively inhibits an imatinib-resistant fusion tyrosine kinase FIP1L1-PDGFRα mutant T674I, analogous to the BCR-ABL T315I mutant (37) . Here we show that the stable expression of TPsiRNA enhances PKC412-mediated killing of TEL-PDGFβR T681I-transformed cells. These findings indicate the feasibility of a combination strategy to overcome drug resistance.
In conclusion, this retroviral system for the delivery and stable expression of siRNA, as well as the strategy to design sequence-specific siRNA targeting the fusion junctions can be used to specifically inhibit chimeric oncogenic genes that are expressed as a consequence of aberrant chromosomal translocations such as BCR-ABL and TEL-PDGFβR, or deletions such as FIP1L1-PDGFRα (1, 38) . Targeting the fusion junction may decrease the likelihood of nonspecific toxicities due to inhibition of the respective wild-type alleles of the fusion genes. Most small molecule inhibitors, including imatinib, are selective rather than specific. This may be an advantage in that leukemias and certain solid tumors associated with mutational activation of ABL, PDGFβR, PDGFRα or KIT may be effectively treated with a single agent, such as imatinib. However, it is also possible that a broad range of specificity could contribute to the toxicities of small molecule kinase inhibitors when used either alone or in combination with other agents. In addition, it is clear that, although drugs like imatinib are remarkably effective, they are disease-remitting agents rather than curative, and that clinical resistance develops to these drugs when they are used as single agents (2, (6) (7) (8) (9) . Finally, although small molecule inhibitors have shown great promise for the treatment of cancer, there are no small molecule inhibitors currently available for clinical use for a number of fusion kinases, including NPM-ALK (28) and ZNF198-FGFR1 (39) . For these reasons, alternative molecularly targeted therapies, including the application of inhibitory siRNA, are under development in a variety of contexts that might enhance specificity and overcome the problem of resistance. Although the efficient delivery of siRNA to target cells will be a challenging problem, our data indicate that the use of siRNA in combination with other molecularly targeted therapies may have therapeutic value.
